**Name of Journal: *World Journal of Gastrointestinal Oncology***

**Manuscript NO: 47439**

**Manuscript Type: ORIGINAL ARTICLE**

***Case Control Study***

**Toll-like receptor 9 polymorphisms and *Helicobacter pylori* influence gene expression and risk of gastric carcinogenesis in the Brazilian population.**

SusiMD *et al.* TLR9 and *Helicobacter pylori* in gastric diseases

**Manoela Dias Susi, Caroline de Matos Lourenço, Lucas Trevizani Rasmussen,Spencer Luis Marques Payão, Ana Flávia Teixeira Rossi, Ana Elizabete Silva, Juliana Garcia de Oliveira-Cucolo**

**Manoela Dias Susi, Caroline de Matos Lourenço,** Department of Graduate-Level Research, USC-Sacred Heart University, Bauru 17011-970, SP, Brazil

**Lucas Trevizani Rasmussen,Spencer Luis Marques Payão,** Department of Genetics and Molecular Biology, FAMEMA-Marilia Medical School, Marília 17519-030, SP, Brazil

**Ana Flávia Teixeira Rossi, Ana Elizabete Silva,** Department of Biology, São Paulo State University-UNESP, São José do Rio Preto 15054-000, SP, Brazil

**Juliana Garcia de Oliveira-Cucolo,** FAMERP-São José do Rio Preto School of Medicine, São José do Rio Preto 15090-000, SP, Brazil

**ORCID number:** Manoela Dias Susi (0000-0001-7913-2564); Caroline de Matos Lourenço (0000-0003-3629-1447); Lucas Trevizani Rasmussen (0000-0002-9033-2257);Spencer Luis Marques Payão (0000-0003-43737742); Ana Flávia Teixeira Rossi (0000-0002-3476-2885); Ana Elizabete Silva (0000-0003-1491-8878); Juliana Garcia de Oliveira-Cucolo (0000-0002-2125-9930).

**Author contributions:** de Oliveira-Cucolo JG and Silva AE conceived and designed the experiments; Susi MD, de Matos Lourenço C, Rossi AF and de Oliveira-Cucolo JG performed the experiments; de Oliveira-Cucolo JG, Silva AE and Rossi AF analyzed and interpreted the data; Rasmussen LT, Payão SLM and Silva AE contributed with the collection of samples/reagents/materials and analysis tools; de Oliveira-Cucolo JG, Rossi AF and Silva AE drafted the manuscript and revised it; All of the authors have approved the final version of manuscript for publication.

**Supported by** theSão Paulo Research Foundation (FAPESP), NO. 2013/14022-6 and NO. 2014/17716-1.

**Institutional review board statement:** This study was approved by the research ethics committee of USC-Sacred Heart University.

**Informed consent statement:** Informed consent was obtained from each patient.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Data sharing statement:** Participants gave written informed consent for data sharing.

**STROBE statement:** The manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Ana Elizabete Silva, PhD, Adjunct Professor,** Department of Biology, São Paulo State University-UNESP, Rua Cristóvão Colombo 2265, São José do Rio Preto 15054-000, SP, Brazil. ae.silva@unesp.br

**Telephone:** +55-17-32212384

**Fax:** +55-17-322212390

**Received:** March 14, 2019

**Peer-review started:** March 14, 2019

**First decision:** May 9, 2019

**Revised:** July 26, 2019

**Accepted:** August 27, 2019

**Article in press:** August 27, 2019

**Published online:** November 15, 2019

**Abstract**

***BACKGROUND***

Toll-like receptors (TLRs) are the first line of host defense, and are involved in *Helicobacter pylori* (*H. pylori*)recognition and activation of both inflammatory and carcinogenic processes. The presence of single nucleotide polymorphisms (SNPs) in genes that activate the immune response may modulate the risk of precancerous lesions and gastric cancer (GC). Among them, Toll-like receptor 9 (TLR9) polymorphisms have emerged with a risk factor of infectious diseases and cancer, however the studies are still inconclusive.

***AIM***

To evaluate whether TLR9rs5743836 and rs187084 SNPs contribute to the risk of gastric carcinogenesis, and its influence on mRNA expression.

***METHODS***

A case-control study was conducted to evaluate two TLR9 SNPs (TLR9*-*1237 TC-rs5743836 and TLR9*-*1486 CT-rs187084) in chronic gastritis (CG) and GC patients. A total of 609 DNA samples of peripheral blood [248 CG, 161 GC, and 200 samples from healthy individuals (C)] were genotyped by polymerase chain reaction-restriction fragment length polymorphism. All samples were tested for the *H. pylori* infection using Hpx1 and Hpx2 primers. Quantitative polymerase chain reaction by TaqMan® assay was used to quantify TLR9mRNA from fresh gastric tissues (48 GC, 26 CG, and 14 C).

***RESULTS***

For TLR9*-*1237, the TC + CC or CC genotypes were associated with a higher risk of GC than C [recessive model odds ratio (OR) = 5.01, 95% confidence interval (CI): 2.52-9.94, *P* < 0.0001], and the CG (recessive model OR =4.63; 95%CI: 2.44-8.79, *P* < 0.0001) groups. For TLR9-1486, an association between the CT + TT genotypes and increased risk of both GC (dominant model OR = 2.72, 95%CI: 1.57-4.72, *P* < 0.0001) and CG (dominant model OR = 1.79, 95%CI: 1.15-2.79, *P* = 0.0094) was observed when compared to the C group. Moreover, the presence of TLR9-1237 TC/CC + TLR9-1486 CC genotypes potentiate the risk for this neoplasm (OR = 18.57; 95%CI: 5.06-68.15, *P* < 0.0001). The TLR9mRNA level was significantly higher in the GC group (RQ = 9.24, *P* < 0.0001) in relation to the CG group (RQ = 1.55, *P* = 0.001) and normal mucosa (RQ = 1.0). When the samples were grouped according to the polymorphic genotypes and the presence of *H. pylori* infection*,* an influence of TLR9-1237 TC + CC polymorphic genotypes (*P* = 0.0083) and *H. pylori* infection (*P* < 0.0001) was observed on the upregulation of mRNA expression.

***CONCLUSION***

Our findings show that TLR9 rs5743836 and rs187084 polymorphisms are associated with a higher risk of carcinogenesis gastric, and that TLR9 mRNA levels can be modulated by TLR9-1237 TC + CC variant genotypes and *H. pylori* infection.

**Key words:** Toll-like receptor 9; *Helicobacter pylori*; Gastric cancer; Chronic gastritis; Polymorphisms; Gene expression

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study investigated the influence of Toll-like receptor 9 (TLR9) polymorphisms on mRNA and *Helicobacter pylori* (*H. pylori*) infection in gastric cancer samples, and the association of these single nucleotide polymorphisms with the risk of developing this neoplasm. Increased expression of TLR9 in tumor tissue was observed compared with chronic gastritis and normal tissue. Moreover, when samples were grouped according to *H. pylori* presence*,* an upregulation of TLR9 mRNA expression was observed. Thus, both *H. pylori* infection as well as functional TLR9 polymorphisms may change gene expression levels, accentuating inflammation and aggravating the development of gastric cancer.

**Citation:** Susi MD, de Matos Lourenço C, Rasmussen LT,Payão SLM, Rossi AF, Silva AE, de Oliveira-Cucolo JG. Toll-like receptor 9 polymorphisms and Helicobacter pylori influence gene expression and risk of gastric carcinogenesis in the Brazilian population. *World J Gastrointest Oncol* 2019; 11(11): 998-1010

URL: https://www.wjgnet.com/1948-5204/full/v11/i11/998.htm

DOI: https://dx.doi.org/10.4251/wjgo.v11.i11.998

**INTRODUCTION**

Toll-like receptors (TLRs) are a class of transmembrane receptors known as pattern recognition receptors. They consist of a family of eleven human proteins (TLR1 to TLR11) and are composed of extracellular, transmembrane, and intracellular regions[1]. The extracellular region consists of ten to thirty leucine-rich repeats, which detect conserved molecular patterns (PAMPs) shared by most microorganisms, including the *Helicobacter pylori (H. pylori)* bacterium, widely known as a class I carcinogen in gastric diseases[1,2]. Thus, the pattern of the host’s immune response beyond genetic and environmental factors is essential for understanding the pathology of gastric cancer (GC)[3].

*H. pylori* infection disrupts gastric homeostasis within the local mucosa and promotes the production of multiple inflammatory cytokines[4]. The inflammatory process can progress through a multi-step process, developing from chronic gastritis (CG) to gastric atrophy, intestinal metaplasia, dysplasia, and finally to GC[2].

After microorganism infection, TLRs are the first line of host defense. They are important components of innate immunity and are involved in the activation of the adaptive immune response[5]. Thus, during *H. pylori* infection, TLRs on gastric epithelial and immune cells recognize many PAMPs. Toll-like receptors 2 and 4 recognize lipopolysaccharides, Toll-like receptor 5 recognizes flagellin, and Toll-like receptor 9 (TLR9) recognizes unmethylated CpG oligonucleotides, which are abundant in bacterial DNA[6]. Based on the recognition and activation of these receptor signaling pathways, the inflammatory process and the presence of genetic polymorphisms may modulate the risk of developing precancerous gastric lesions and GC[5].

The activation of TLR9 requires a complex pathway, since it is located in the intracellular compartment of endosomes. It is therefore believed that unmethylated CpG oligonucleotides are transferred to the intracellular compartment through non-specific endocytosis[7].

Some TLR9 polymorphisms (rs352139, rs187084, rs41308230, and rs5743844) have been associated with infection-related diseases, such as tuberculosis, malaria, and lupus, as well as with liver cancer, GC, and colorectal cancer[5,7-11].

TLR9-1237 TC (rs5743836), which replaces tyrosine with cytosine within the proximal promoter region, has had its variant allele TLR9-1237 C associated with the development of premalignant gastric diseases induced by *H. pylori*[10,12]. However, another study on an Asian population did not detect an association between a risk for GC and *H. pylori* infection[9].

In the case of TLR9-1486 C/T (rs187084), which is located in the promoter region, it is not yet clear which alleles (C or T) are associated with susceptibility to disease. Some studies have indicated an association between the CT or CC genotypes and a greater risk of cervical cancer[12,13]. Conversely, a recent study found a protective association between the CT genotype and the risk of severe bronchiolitis[14].

Given inconsistent results, as well as the importance of these receptors in the immune response and the susceptibility to inflammatory diseases and cancer, new studies are needed. Thus, the aim of this study was to evaluate whether the TLR9-1237 TC (rs5743836) and TLR9-1486 CT *(*rs187084) polymorphisms (alone and in combination) are associated with a risk of CG and GC. In addition, we also evaluate the influence of both polymorphisms and *H. pylori* infection on TLR9 mRNA expression. Our results show that both single nucleotide polymorphisms (SNPs) already play a major role in the early stages of the gastric carcinogenic cascade.

**MATERIALS AND METHODS**

***Ethics statement***

Written informed consent for the collection of biological material (peripheral blood and gastric tissues) and access to medical records for research purposes was obtained from all individuals included in the study. The Research Ethics Committee of Sacred Heart University in Bauru, São Paulo, Brazil approved this study (Registration NO. 382.514).

***Subjects and samples***

First, a case-control study on CG, GC, and healthy individuals (C) was performed on a total of 609 DNA samples obtained from peripheral blood, which were genotyped for TLR9 polymorphisms (rs187084 and rs5743836). All of the samples included were obtained from patients with gastric complaints who were treated in the Gastroenterology Department of the Clinical Hospital of Marília Medical School in Marília-São Paulo or in the State Hospital of Bauru, São Paulo, Brazil. These patients received upper digestive endoscopies between January 2010 and March 2015. None of the subjects received chemotherapy drugs, radiotherapy, antibiotics, anti-inflammatory agents, or proton pump inhibitors before 30 days of endoscopy.

The CG group consisted of 248 patients (110 men and 138 women; mean age: 43.10 ± 21.79 years, range: 10-90 years) with a confirmed histopathological diagnosis of CG as per the Sidney System[15], while the GC group included 161 patients (111 men and 50 women; mean age: 63.33 ± 14.45 years, range: 23-90 years) with a confirmed histopathological diagnosis of GC as per Lauren’s classification[16]. The control group (C) consisted of 200 healthy individuals free of gastric diseases (97 men and 103 women; mean age: 49.58 ± 21.01 years, range: 10-90 years) who underwent gastric endoscopy and were confirmed negative for any gastric disease, as well as for *H. pylori* infection.

In addition, biopsies of fresh gastric tissues were also collected for quantification of TLR9 mRNA. Biopsies were mainly collected from the gastric antrum and corpus regions during endoscopic evaluation or gastric surgery of 48 patients with CG (29 men and 19 women; mean age: 53.10 ± 9.41 years, range: 41-84 years), 26 patients with GC (19 men and 7 women; mean age: 62.77 ± 14.20 years, range: 33-88 years), and 14 individuals who were *H. pylori*-negative and free of gastric diseases as tested by histopathology (9 men and 5 women; mean age: 49.58 ± 21.01 years, range: 10-92 years).

***Polymorphism genotyping and H. pylori status***

DNA from peripheral blood was extracted following the protocol by[17], while DNA from fresh gastric tissue was extracted using the QIAamp® tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions and stored at -20 °C. The polymerase chain reaction-restriction fragment length polymorphism technique was used to identify the TLR9-1486 CT (rs187084) andTLR9*-*1237 TC (rs5743836) SNPs in all three groups. Table 1 summarizes the polymerase chain reaction (PCR) conditions, sets of primers, enzymes used in each assay, minor allele frequency (MAF), and location for both polymorphisms. Approximately 10% of the samples were processed in duplicate for quality control. The presence of *H. pylori* was detected using PCR where a 150 bp fragment was amplified from genomic DNA samples using Hpx1 and Hpx2 primers, as described in a previous study[18].

***RNA extraction and reverse transcription***

Total RNA was extracted using a RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. RNA concentrations and quality were measured using the NanoDrop 2000 spectrophotometer (ThermoFisher Scientific, Waltham, MA, United States). The RNA samples were stored at 80°C and used for reverse transcription. cDNA was synthesized from 2.5 μg of total RNA using random primers and a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, United States) according to the manufacturer’s instructions.

***Real-time quantitative polymerase chain reaction***

The relative expression levels of TLR9 mRNA were measured by real-time quantitative PCR based on the TaqMan® System (Life Technologies, Carlsbad, CA, United States) within the StepOne Plus Real-Time PCR system 2.2.3 (Applied Biosystems) using a specific TaqMan probe for TLR9 (H00002973\_m1) and two reference genes, GUSB (Hs00187320\_m1) and TBP (Hs00187332\_m1) which were tested in a previous study[19]. A pool of normal *H. pylori-*negative gastric tissue samples was used as a calibrator. All reactions were performed in triplicate and included a negative reaction control. To determine the amplification efficacy of the probe, a standard curve was constructed with serial dilutions of cDNA samples (pool of pure cDNA and 1:5, 1:25, 1:125, and 1:625 dilutions). Relative quantification (RQ) was calculated using the comparative CT method (2(-∆∆Ct))[20], while using a pool of the normal mucosa samples as calibrator and reference genes for normalization. The data were expressed as median values.

***Statistical analysis***

We evaluated MAF and the Hardy-Weinberg equilibrium (HWE) using OEGE software[21]. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for the polymorphisms under study using multiple logistic regression models adjusted for age, gender, and *H. pylori* infection. ORs were calculated using the SNPStat program, which considered the dominant model (major allele homozygotes *vs* heterozygotes + minor allele homozygotes), the recessive model (major allele homozygotes + heterozygotes *vs* minor allele homozygotes), and the log-additive model (major allele homozygotes *vs* heterozygotes *vs* minor allele homozygotes for the two polymorphisms). The haplotype frequencies of TLR9were inferred using the Haploview program, version 4.0. Data regarding the relative expression of mRNA were expressed as a median to determine possible associations between the differences in relative gene expression in each group. The distribution of continuous data was evaluated using the D’Agostino and Pearson omnibus normality test. Wilcoxon Signed Rank test was used to compare the expression values between the CG and GC groups in relation to normal mucosa. The Mann-Whitney test was used to analyze the influence of the factors as variant genotypes and *H. pylori* infection on TLR9 mRNA expression. Statistical analyses were performed using the GraphPad Prism 5 software, version 5.01, and the SPSS program, version 11.5. A probability level (*P*) of < 0.05 was considered significant.

**RESULTS**

***TLR9-1237 T/C and TLR9-1486 C/T polymorphisms, risk of CG and GC***

The rs5743836 and rs187084 SNPs were found not to be in HWE in the GC (*P* < 0.0001), CG (*P* < 0.0001), and C (*P* = 0.0008) groups. The results of the genotype and allele frequencies for the TLR9*-*1237 TCand TLR9*-*1486 CT polymorphisms in all three groups (GC *vs* C, CG *vs* C, and GC *vs* CG) are shown in Table 2.

For TLR9*-*1237TC, both TC + CC and solely CC genotype were associated with a risk of GC in all three evaluated models, whether compared to each other or relative to the C groupdominant model (OR = 3.03, 95%CI: 1.95-4.71, *P* < 0.0001), recessive model (OR = 5.01, 95%CI: 2.52-9.94, *P* < 0.0001), and log-additive model (OR = 2.37, 95%CI: 1.74-3.23, *P* < 0.0001)], as well as compared to the CG group [dominant model (OR = 3.46, 95%CI: 2.23-5.37, *P* < 0.0001), recessive model (OR = 4.63, 95%CI: 2.44-8.79, *P* < 0.0001), and log-additive model (OR = 2.46, 95%CI: 1.82-3.34, *P* < 0.0001)]. However no association was found between CG *vs* C [dominant model (OR = 0.91, 95%CI: 0.59-1.40, *P* = 0.6600), recessive model (OR = 1.08, 95%CI: 0.50-2.34, *P* = 0.8400), and log-additive model (OR = 0.96, 95%CI: 0.70-1.32, *P* = 0.8100)] (Table 2).

For TLR9-1486 CT, the CT + TT polymorphic genotypes were also associated with risk of GC in the dominant model (OR = 2.72, 95%CI: 1.57-4.72), *P* < 0.0001) and in the log-additive model (OR = 1.70, 95%CI: 1.23-2.37, *P* = 0.0013) relative to the C group. Additionally, between the CG and C groups, we observed a higher risk associated for the CT + TT and also the TT genotype in the three evaluated models [dominant model (OR = 1.79, 95%CI: 1.15-2.79, *P* = 0.0094), recessive model (OR = 1.65, 95%CI: 1.05-2.61, *P* = 0.0300), and log-additive model (OR = 1.52, 95%CI: 1.15-2.02, *P* = 0.0030)]. However, no statistically significant difference was observed between the two case groups (Table 2).

The TLR9 haplotype analysis (Table 3) revealed a higher frequency of the two wild alleles (T-C haplotype) in the C group than in the GC group (47.7 and 35.2, respectively; *P* ≤ 0.0001), or in the CG group (48.4 and 40.5, respectively; *P* = 0.0178). Similarly, a higher frequency of T-C haplotype was also found in the CG group than in the GC group (39.7 and 24.9, respectively; *P* ≤ 0.0001). However, the opposite was observed for the variant haplotype C-T, which was more frequent in the GC group than in the C group (18.7 and 8.2, respectively; *P* ≤ 0.0001), as well as in relation to the CG group (18.3 and 9.0, respectively; *P* ≤ 0.0001).

In another statistical analysis, when we evaluated the different combinations between the genotypes of the two polymorphisms (TLR9-1237 TC + TLR9-1486 CT), OR was found to be higher in the two case groups relative to the control group, as well as in the GC group relative to the CG group (Table 4). The highest OR values were observed for the combination TLR9-1237 TC/CC + TLR9-1486 CC when the GC group was compared to the C group (OR = 18.57, CI: 5.06-68.15, *P* < 0.0001), and when the GC group was compared to the CG group (OR = 10.08, CI: 2.96-34.24, *P* = 0.0002). Elevated OR values were also observed for the combination TLR9-1237 TC/CC + TLR9-1486 CT/TT when the GC group was compared to the C group (OR = 10.79, CI: 4.50-25.83, *P* < 0.0001).

***TLR9 mRNA expression in gastric lesions and H. pylori infection***

The relative expression of TLR9 in the GC and CG groups is shown in Table 5 and Figure 1. Higher mRNA expression was observed in the GC group (median RQ = 9.24, *P* < 0.0001) and the CG group (median RQ = 1.55, *P* = 0.001) relative to normal mucosa, as was significant upregulation in the GC group relative to the CG group (*P* < 0.0001).

In addition, an analysis was performed to determine the influence of *H. pylori* infection on TLR9mRNA levels. The GC and CG tissue samples were considered together to compare the positive and negative *H. pylori* samples, and significantly higher TLR9 expression was demonstrated among samples that were *H. pylori-*positive (median RQ = 2.85) than among *H. pylori-*negative samples (median RQ = 0.86, *P* < 0.0001; Figure 2).

***Influence of -1237 T/C and -1486 C/T TLR9 polymorphisms on mRNA expression in GC and CG***

Posteriorly, the GC and CG samples were grouped according to the polymorphic genotypes for TLR9-1237T/Cand -1486 C/Tin order to assess whether these polymorphisms affect TLR9 mRNA expression levels (Table 6 and Figure 3).

In the GC group, individuals carrying the TLR9-1237 TC + CC polymorphic genotype exhibited higher mRNA expression levels (RQ = 13.01) than the TT wild-type genotype carriers (RQ = 5.24, *P* = 0.0083). However, in the CG group, differences between the TC + CC and TT wild-type genotypes were not statistically significant (*P* = 0.8442). ForTLR9*-*1486 CT, in both the GC and the CG groups, when the individuals were grouped according to T allele carriers (CT + TT) and as CC wild-type homozygous, the differences were not significant (*P* = 0.8763 and 0.1515, respectively).

**DISCUSSION**

Our findings show that the functional polymorphisms TLR9-1237 T/C- (rs5743836) and TLR9-1486 C/T (rs187084) receptors are associated with an increased risk of developing premalignant and malignant gastric diseases in this Brazilian population. Therefore, they may act as a potential factor in the progression of gastric carcinogenesis. TLR9 mRNA expression levels are upregulated in GC tissues, and are modulated by both *H. pylori* infection and the presence of TLR9-1237 TC + CC variant genotypes.

In our analyses, the case and control groups were not found to be in HWE; however, this disequilibrium does not invalidate the association observed in this study, since the groups are part of the same population. It is important to note that this theorem assumes an ideal population in which allele and genotype frequencies remain constant from generation to generation in the absence of other evolutionary influences. In genes such as those involved in the control of inflammatory and immunity diseases or cancer, this imbalance in HWE may appear to be associated with the selection of a particular allele, which allows for more effective protection or response[21].

The first meta-analysis to investigate the association of these two TLR9 polymorphisms with the susceptibility to cancer evaluated 11 studies on various ethnic groups, and failed to demonstrate any influence of rs187084 or rs5743836 SNPs. This study did, however, indicate that rs352140, in the TLR9 2848 C/T gene, was associated with an increased cancer risk in Caucasians[22]. One study in a Mexican population also did not find an association of TLR9 1237 T/C SNP with gastroduodenal diseases, yet found that the TLR9 2848 G allele increased the risk of duodenal ulcers and *H. pylori* infection[23]. Thus, despite that both cited studies differed from our TLR9 1237 T/C SNP results, it is necessary to investigate TLR9 2848 C/T (rs352140) in our Brazilian population in future analyses.

Another study analyzed the influence of three TLR9 polymorphisms on multiple cancers, and in the case of the TLR9-1237 TC (rs5743836) SNP, found a protective effect of the C variant allele on digestive system tumors and breast cancer. In contrast to the SNP TLR9-1486 CT (rs187084), there was a high risk for C wild allele carriers in cancer development, particularly in the case of cervical cancer in both the Chinese[13,24] and Caucasian populations[25]. Tian *et al*[13] stratified the population by race to eliminate heterogeneity, and demonstrated for the rs187084 SNP that the influence of heterogeneity decreased when stratified only among the Chinese population. These results are inconsistent with those found in the present study, and thus reflect the complexity of studies on genetic associations with predisposition to diseases, since it involves several factors, such as ethnic origin, lifestyle, gene-environment interactions, and sample size[14,26-28].

On the other hand, Gębura *et al*[29] found results similar to ours in patients with rheumatoid arthritis. They evaluated certain SNPs on TLRs in a Caucasian population, and were able to demonstrate a positive association between the TLR9-1237 C and TLR9-1486 T variants and susceptibility to the development of rheumatoid arthritis. However, TLR9-1486 T was found to be associated with the disease only among women. Similarly, in cervical cancer and pre-neoplastic cervical lesions, Martínez-Campos*et al*[26] found a positive association between the TLR9-1486 TT genotype and the diseases, but did not detect any association between the TLR9-1237 TC SNP and the lesions evaluated.

In a Brazilian population, a single study that assessed various SNPs, among them the TLR9-1486 C/T, reported a protective association between the TLR9-1486 C allele or CT genotype and the severity of bronchiolitis caused by rhinovirus, with a higher expectation of intensive care hospitalization[14].

Few studies have investigated the association between TLR9 polymorphisms and the risk of GC, and most of those have focused on the Asian populations [9,10,27,30]. Liu *et al*[30] failed to demonstrate an association between TLR9-1486 CT SNPs and GC risk; meanwhile, Wang *et al*[9]were able to demonstrate an association between both the CT and CC genotypes of TLR9-1486 and a higher risk of GC, as well as an association with the presence of *H. pylori*. The authors suggest that TLR9-1486 C carriers are associated with an increased risk and poor prognosis of gastric carcinoma in the Chinese population. However, they could not find any individuals with the C allele for the TLR9-1237 T/C polymorphism, and all individuals were genotyped as TLR9-1237 TT. Conversely, Ng *et al*[10]found an association between the C variant allele of TLR9-1237 and the development of *H. pylori-*induced premalignant gastric lesions.

We were able to demonstrate that variant haplotypes (C-T) for the TLR9 -1237 and -1486 SNPs were more frequent in the GC and CG groups than the control group. Moreover, the combination of two risk alleles,homozygous or heterozygous (TLR9-1237 TC/CC + TLR9-1486 CT/TT) also conferred higher ORs, a result which suggests a synergistic or addictive effect of these variant alleles and the risk of gastric lesions. Ashton *et al*[31]performed the haplotype analysis for TLR9 (TLR9-1237 TC/CC + TLR9-1486 CT/TT) in endometrial cancer, but found a higher presence of the C-C combination in the case group than in the C group. In this population, the TLR9-1486 C allele was considered the least frequent variant. Another study that evaluated the frequency of four SNPs on TLR9 (rs187084, rs352139, rs5743836, and rs352140) found a significantly higher frequency of CATT in patients with lupus erythematous relative to control groups[32].

Despite this variability of the effect of wild-type and polymorphic alleles on the risk of inflammatory diseases and cancer, Omar *et al*[33] were able to demonstrate the synergistic effect of the TLR9 TTAG (-1486 T, -1237 T, + 1174 A, + 2848 G) haplotype on promoter activity. This TTAG haplotype was significantly associated with protection against malaria, and these findings were strongly supported by the result of luciferase reporter gene expression assay, which showed a significantly higher promoter activity for the TTA haplotype relative to the CCG, CTG, and TCG haplotypes. Therefore, the presence of the wild-type or variant alleles may influence the levels of TLR9 mRNA.

When we analyzed the TLR9mRNA expression, we also found significantly higher levels of TLR9 mRNA in GC and CG tissues, as well as upregulation of TLR9expression in the *H. pylori-*positive samples, regardless of the type of lesion (cancer or gastritis). Moreover, we observed that carriers of the TLR9-1237 TC + CC genotypes also exhibit higher TLR9 expression levels than the TT genotype, a finding which supports the hypothesis that infection by *H. pylori* triggers inflammatory responses mediated by TLR receptors, the expression of which may be affected by the occurrence of polymorphisms in their promoter regions.

The TLR9-1237 TC (rs5743836) SNP is located in the promoter region, and an *in silico* study found that the C variant allele creates an alternative NF-κB binding site, which may be functionally relevant. It is believed to enhance the transcriptional activation of TLR9and potentially affect CpG-DNA activation of pro-inflammatory cytokines, consequently exacerbating the inflammatory response[10]. Moreover, functional studies have demonstrated that C variant allele carriers exhibit significantly higher luciferase activity, indicating that rs5743836 regulates TLR9 transcriptional activity[10].

Mutations in the promoter region have been predicted to affect the expression or stability of regulatory regions[34], a theory which would explain the higher expression levels of TLR9 mRNA in GC tissues, particularly for TLR9-1237 C allele carriers.

The presence of *H. pylori* in the gastric mucosa is a preponderant factor for carcinogenesis. The vast majority of these host colonies are free-living, but it is known that this bacterium can bind strongly to gastric epithelial cells and induce humoral and cellular immune responses, and may also cause ultra-structural changes in these cells[28]. However, *H. pylori* lipopolysaccharide is not a good immune system activator, so the creation of an alternative NF-κB binding site generated by the presence of TLR9-1237 C variant allele would cause a greater inflammatory response and facilitate the carcinogenic process[35].

Regarding TLR9-1486 C/T (rs187084), an *in silico* analysis showed that this SNP created a putative Sp1 binding site, which may be functionally relevant[36]. Recently, Martínez-Campos *et al*[26] found both upregulation of TLR9 mRNA in peripheral blood mononuclear cells and a higher concentration of TLR9 protein in the sera of patients diagnosed with uterine cervical cancer and human papillomavirus. However, no significant difference was observed in TLR9expression levels among CC, TC, and TT carriers of TLR9-1486 SNP, a finding which was likely due to the limited sample size.

In conclusion, our results demonstrate that TLR9-1237 TC + CC and TLR9-1486 TC + TT, whether alone or in combination, are associated with risk of gastric carcinogenesis in the Brazilian population. Moreover, the results suggest that upregulation of TLR9 mRNA levels in premalignant and malignant gastric tissues may be influenced by TLR9-1237 TC + CC variant genotypes. The pattern of the host’s immune response, along with genetic and environmental factors, are essential for understanding the pathology of GC. Thus, polymorphisms in genes that affects its expression, such as TLR9, could have an effect on the development and clinical manifestation of disease.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer (GC) is one of the most prevalent cancers worldwide, with high rates of incidence and death. It ranks sixth in the world and is the fifth leading cause of cancer-related deaths worldwide. In Brazil, GC is the fourth most frequent type of cancer in men, and the sixth in women, with an estimated incidence of 21,290 new cases in 2018. The main risk factor associated with this type of cancer is the infection by the bacterium *Helicobacter pylori* (*H. pylori*). Toll-like receptors are the first line of host defense, and are involved in *H. pylori* recognition and activation of the inflammatory and carcinogenic process. The presence of single nucleotide polymorphisms (SNPs) in genes that activate the immune response may modulate the risk of precancerous lesions and GC, among them of which is TLR9 polymorphisms.

***Research motivation***

Polymorphisms in toll-like receptors genes have emerged with a risk factor of infectious diseases and cancer. However, the literature presents conflicting results. Therefore, several studies are needed to assess and confirm the real role among factors that influence changes in immune inflammatory processes related to GC, especially when it is a mixed population such as the Brazilian population.

***Research objectives***

Considering the inconsistent results and the importance of these receptors in the immune response and to susceptibility to inflammatory diseases and cancer, new studies are needed. Thus, the aim of this study was to evaluate whether the TLR9-1237 TC (rs5743836) and TLR9-1486 CT(rs187084) polymorphisms (alone and in combination) are associated with a risk of chronic gastritis (CG) and GC. In addition, we also evaluate the influence of both polymorphisms and *H. pylori* infection on TLR9 mRNA expression. The results may highlight important polymorphisms that act on gastric carcinogenesis.

***Research methods***

A case-control study was conducted to evaluate two TLR9 SNPs (TLR9*-*1237 TC-rs5743836 and TLR9*-*1486 CT-rs187084) in CG and GC patients. A total of 609 DNA samples of peripheral blood [248 CG, 161 GC, and 200 samples from healthy individuals (C)] were genotyped by polymerase chain reaction-restriction fragment length polymorphism. All samples were tested for the *H. pylori* infection using Hpx1 and Hpx2 primers. Quantitative polymerase chain reaction by TaqMan® assay was used to quantify TLR9mRNA from fresh gastric tissues (48 GC, 26 CG, and 14 C).

***Research results***

The data showed that for TLR9-1237, the TC + CC or CC genotypes were associated with a higher risk of GC than the C and CG groups. For TLR9-1486, an association between the CT + TT genotypes and increased risk of both GC and CG was observed when compared to the C group. Moreover, the presence of TLR9-1237 TC/CC + TLR9-1486 CC genotypes potentiates the risk for this neoplasm. The TLR9mRNA level was significantly higher in the GC group in relation to the CG group and normal mucosa. When the samples were grouped according to the polymorphic genotypes and the presence of *H. pylori* infection*,* an influence of TLR9-1237 TC + CC polymorphic genotypes and *H. pylori* infection was observed on the upregulation of mRNA expression.

***Research conclusions***

Our findings highlight that the functional polymorphisms of the TLR9-1237 T/C (rs5743836) and TLR9-1486 C/T (rs187084) receptors are associated with an increased risk of developing premalignant and malignant gastric diseases in this Brazilian population, and therefore may act as a potential factor in the progression of gastric carcinogenesis. TLR9 mRNA expression levels are upregulated in GC tissues and are modulated by both *H. pylori* infection and the presence of TLR9-1237 TC + CC-variant genotypes. The pattern of the host’s immune response, along with genetic and environmental factors, are essential for understanding the pathology of GC. Thus, polymorphisms in genes that affect its expression, such as TLR9, could have an effect on the development and clinical manifestation of disease.

***Research perspectives***

Considering that most cases of GC have a good prognosis and are treatable when diagnosed at an early stage, it is of the utmost importance to establish molecular markers capable of identifying risk groups and providing early diagnosis in individuals with increased risk of developing this neoplasm. Overall, our results indicate that the TLR9 gene plays an important role in gastric carcinogenesis, highlighting the importance of the TLR9-1237 T/C (rs5743836) polymorphism in increasing gene expression and *H. pylori* infection, possibly triggering a stronger inflammatory response, which in turn enhances the risk of tumor progression. In the future, it would be important to investigate another polymorphism in the TLR9 gene [TLR9-2848 C/T (rs352140)], described in the literature as associated with cancer, but not yet analyzed in our Brazilian population.

**Acknowledgements**

The authors are grateful to Joice Matos Biselli and Profa Dra Lilian Castiglioni for her support in the statistical analysis.

**REFERENCES**

1 **Varga MG**, Peek RM. DNA Transfer and Toll-like Receptor Modulation by Helicobacter pylori. *Curr Top Microbiol Immunol* 2017; **400**: 169-193 [PMID: 28124154 DOI: 10.1007/978-3-319-50520-6\_8]

2 **Correa P**. The biological model of gastric carcinogenesis. *IARC Sci Publ* 2004; **(157)**: 301-310 [PMID: 15055303]

3 **Song M**, Rabkin CS, Camargo MC. Gastric Cancer: an Evolving Disease. *Curr Treat Options Gastroenterol* 2018; **16**: 561-569 [PMID: 30361856 DOI: 10.1007/s11938-018-0203-1]

4 **Cadamuro AC**, Rossi AF, Maniezzo NM, Silva AE. Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs. *World J Gastroenterol* 2014; **20**: 1424-1437 [PMID: 24587619 DOI: 10.3748/wjg.v20.i6.1424]

5 **Wang TR**, Peng JC, Qiao YQ, Zhu MM, Zhao D, Shen J, Ran ZH. Helicobacter pylori regulates TLR4 and TLR9 during gastric carcinogenesis. *Int J Clin Exp Pathol* 2014; **7**: 6950-6955 [PMID: 25400780]

6 **Fukata M**, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. *Oncogene* 2008; **27**: 234-243 [PMID: 18176605 DOI: 10.1038/sj.onc.1210908]

7 **Fűri I**, Sipos F, Germann TM, Kalmár A, Tulassay Z, Molnár B, Műzes G. Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects. *World J Gastroenterol* 2013; **19**: 4119-4126 [PMID: 23864774 DOI: 10.3748/wjg.v19.i26.4119]

8 **Lopes JA**, Borges-Canha M, Pimentel-Nunes P. Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis? *World J Hepatol* 2016; **8**: 162-182 [PMID: 26839640 DOI: 10.4254/wjh.v8.i3.162]

9 **Wang X**, Xue L, Yang Y, Xu L, Zhang G. TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. *PLoS One* 2013; **8**: e65731 [PMID: 23776537 DOI: 10.1371/journal.pone.0065731]

10 **Ng MT**, Van't Hof R, Crockett JC, Hope ME, Berry S, Thomson J, McLean MH, McColl KE, El-Omar EM, Hold GL. Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9 -1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. *Infect Immun* 2010; **78**: 1345-1352 [PMID: 20038537 DOI: 10.1128/IAI.01226-09]

11 **Messaritakis I**, Stogiannitsi M, Koulouridi A, Sfakianaki M, Voutsina A, Sotiriou A, Athanasakis E, Xynos E, Mavroudis D, Tzardi M, Souglakos J. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. *PLoS One* 2018; **13**: e0197327 [PMID: 29883450 DOI: 10.1371/journal.pone.0197327]

12 **Chen X**, Wang S, Liu L, Chen Z, Qiang F, Kan Y, Shen Y, Wu J, Shen H, Hu Z. A genetic variant in the promoter region of Toll-like receptor 9 and cervical cancer susceptibility. *DNA Cell Biol* 2012; **31**: 766-771 [PMID: 22059466 DOI: 10.1089/dna.2011.1427]

13 **Tian S**, Zhang L, Yang T, Wei X, Zhang L, Yu Y, Li Y, Cao D, Yang X. The Associations between Toll-Like Receptor 9 Gene Polymorphisms and Cervical Cancer Susceptibility. *Mediators Inflamm* 2018; **2018**: 9127146 [PMID: 30147445 DOI: 10.1155/2018/9127146]

14 **Alvarez AE**, Marson FAL, Bertuzzo CS, Bastos JCS, Baracat ECE, Brandão MB, Tresoldi AT, das Neves Romaneli MT, Almeida CCB, de Oliveira T, Schlodtmann PG, Corrêa E, de Miranda MLF, Dos Reis MC, De Pieri JV, Arns CW, Ribeiro JD. Association between single nucleotide polymorphisms in TLR4, TLR2, TLR9, VDR, NOS2 and CCL5 genes with acute viral bronchiolitis. *Gene* 2018; **645**: 7-17 [PMID: 29253610 DOI: 10.1016/j.gene.2017.12.022]

15 **Dixon MF**, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996; **20**: 1161-1181 [PMID: 8827022 DOI: 10.1097/00000478-199610000-00001]

16 **Lauren P**. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965; 64: 31-49 [PMID: 14320675 DOI: 10.1111/apm.1965.64.1.31]

17 **Miller SA**, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988; **16**: 1215 [PMID: 3344216 DOI: 10.1093/nar/16.3.1215]

18 **Rasmussen LT**, Labio RW, Gatti LL, Silva LC, Queiroz VF, Smith Mde A, Payão SL. Helicobacter pylori detection in gastric biopsies, saliva and dental plaque of Brazilian dyspeptic patients. *Mem Inst Oswaldo Cruz* 2010; **105**: 326-330 [PMID: 20512249 DOI: 10.1590/s0074-02762010000300015]

19 **Zabaglia LM**, Sallas ML, Santos MPD, Orcini WA, Peruquetti RL, Constantino DH, Chen E, Smith MAC, Payão SM, Rasmussen LT. Expression of miRNA-146a, miRNA-155, IL-2, and TNF-α in inflammatory response to Helicobacter pylori infection associated with cancer progression. *Ann Hum Genet* 2018; **82**: 135-142 [PMID: 29250766 DOI: 10.1111/ahg.12234]

20 **Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**: 402-408 [PMID: 11846609 DOI: 10.1006/meth.2001.1262]

21 **Rodriguez S**, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. *Am J Epidemiol* 2009; **169**: 505-514 [PMID: 19126586 DOI: 10.1093/aje/kwn359]

22 **Zhang L**, Qin H, Guan X, Zhang K, Liu Z. The TLR9 gene polymorphisms and the risk of cancer: evidence from a meta-analysis. *PLoS One* 2013; **8**: e71785 [PMID: 23990988 DOI: 10.1371/journal.pone.0071785]

23 **Trejo-de la O A**, Torres J, Sánchez-Zauco N, Pérez-Rodríguez M, Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E, Maldonado-Bernal C. Polymorphisms in TLR9 but not in TLR5 increase the risk for duodenal ulcer and alter cytokine expression in the gastric mucosa. *Innate Immun* 2015; **21**: 706-713 [PMID: 25995217 DOI: 10.1177/1753425915587130]

24 **Mu X**, Zhao J, Yuan X, Zhao X, Yao K, Liu Y, Zhao X. Gene Polymorphisms of Toll-Like Receptor 9 -1486T/C and 2848G/A in Cervical Cancer Risk. *Int J Gynecol Cancer* 2015; **25**: 1173-1178 [PMID: 26270118 DOI: 10.1097/IGC.0000000000000494]

25 **Wan GX**, Cao YW, Li WQ, Li YC, Zhang WJ, Li F. Associations between TLR9 polymorphisms and cancer risk: evidence from an updated meta-analysis of 25,685 subjects. *Asian Pac J Cancer Prev* 2014; **15**: 8279-8285 [PMID: 25339018 DOI: 10.7314/APJCP.2014.15.19.8279]

26 **Martínez-Campos C**, Bahena-Román M, Torres-Poveda K, Burguete-García AI, Madrid-Marina V. TLR9 gene polymorphism -1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population. *J Cancer Res Clin Oncol* 2017; **143**: 2437-2445 [PMID: 28819773 DOI: 10.1007/s00432-017-2495-2]

27 **Liu F**, Lu W, Qian Q, Qi W, Hu J, Feng B. Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to type 2 diabetes and coronary artery disease. *J Biomed Biotechnol* 2012; **2012**: 373945 [PMID: 23091345 DOI: 10.1155/2012/373945]

28 **Mommersteeg MC**, Yu J, Peppelenbosch MP, Fuhler GM. Genetic host factors in Helicobacter pylori-induced carcinogenesis: Emerging new paradigms. *Biochim Biophys Acta Rev Cancer* 2018; **1869**: 42-52 [PMID: 29154808 DOI: 10.1016/j.bbcan.2017.11.003]

29 **Gębura K**, Świerkot J, Wysoczańska B, Korman L, Nowak B, Wiland P, Bogunia-Kubik K. Polymorphisms within Genes Involved in Regulation of the NF-κB Pathway in Patients with Rheumatoid Arthritis. *Int J Mol Sci* 2017; **18**: [PMID: 28677621 DOI: 10.3390/ijms18071432]

30 **Liu S**, Wang X, Shi Y, Han L, Zhao Z, Zhao C, Luo B. Toll-like receptor gene polymorphisms and susceptibility to Epstein-Barr virus-associated and -negative gastric carcinoma in Northern China. *Saudi J Gastroenterol* 2015; **21**: 95-103 [PMID: 25843196 DOI: 10.4103/1319-3767.153832]

31 **Ashton KA**, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Scott RJ. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. *BMC Cancer* 2010; **10**: 382 [PMID: 20646321 DOI: 10.1186/1471-2407-10-382]

32 **Zhang J**, Zhu Q, Meng F, Lei H, Zhao Y. Association study of TLR-9 polymorphisms and systemic lupus erythematosus in northern Chinese Han population. *Gene* 2014; **533**: 385-388 [PMID: 24004541 DOI: 10.1016/j.gene.2013.08.051]

33 **Omar AH**, Yasunami M, Yamazaki A, Shibata H, Ofori MF, Akanmori BD, Shuaibu MN, Kikuchi M, Hirayama K. Toll-like receptor 9 (TLR9) polymorphism associated with symptomatic malaria: a cohort study. *Malar J* 2012; **11**: 168 [PMID: 22594374 DOI: 10.1186/1475-2875-11-168]

34 **Lemos B**, Bettencourt BR, Meiklejohn CD, Hartl DL. Evolution of proteins and gene expression levels are coupled in Drosophila and are independently associated with mRNA abundance, protein length, and number of protein-protein interactions. *Mol Biol Evol* 2005; **22**: 1345-1354 [PMID: 15746013 DOI: 10.1093/molbev/msi122]

35 **Carvalho A**, Osório NS, Saraiva M, Cunha C, Almeida AJ, Teixeira-Coelho M, Ludovico P, Pedrosa J, Pitzurra L, Aversa F, Romani L, Castro AG, Rodrigues F. The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation. *PLoS One* 2011; **6**: e28256 [PMID: 22132241 DOI: 10.1371/journal.pone.0028256]

36 **Hamann L**, Hamprecht A, Gomma A, Schumann RR. Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor -2, -4, and -9 genes. *J Immunol Methods* 2004; **285**: 281-291 [PMID: 14980441 DOI: 10.1016/j.jim.2003.12.005]

**P-Reviewer:** Romo-Gonzalez C, Islek A **S-Editor:** Tang JZ

**L-Editor:** Filipodia **E-Editor:** Qi LL

**Specialty type:** Oncology

**Country of origin:** Brazil

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1** **Nucleotide primer sequences, polymerase chain reaction conditions and minor allele frequency for polymorphisms TLR9-1237 T/C (rs5743836) and -1486 T/C (rs187084)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Genes** | **Location** | **MAF** | **Primers, 5’-3’** | **Cycles** | **T melting** | **Enzyme** | **Genotypes, bp** |
| TLR9-1237 T/C  *(*rs5743836) | Chromosome 3: 52226766 (intron variant) | 0.1725  (C) | F: TGGGAGCAGAGACATAATGGA R: CTGCTTGCAGTTGACTGTGT | 35 | 60 ℃ | *BstNI* | CC = 60 + 48 + 27  CT = 108 + 60 + 48 + 27  TT = 108 + 27 |
| TLR9-1486 C/T(rs187084) | Chromosome 3: 52227015 (intron variant) | 0.3776  (C) | F: TCCCAGCAGCAACAATTCATTA  R: CTGCTTGCAGTTGACTGTGT | 30 | 60 ℃ | *AflII* | CC = 499  TC = 499 + 327 + 172  TT = 327 + 172 |

Minor allele frequency was extracted from 1000 Genomes Project Phase 3. MAF: Minor allele frequency.

**Table 2** **Genotype and allele frequencies of TLR9*-*1237 T/CandTLR9*-*1486 C/TSNPs in both case and control groups (GC *vs* C, CG *vs* C, and GC *vs* CG)**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Polymorphisms** | **Models** | | **Genotypes/Alleles** | | **C**  ***n* = 200** | **Cases** | | | | | |
| **GC** | | | **CG** | | |
| ***n* = 161** | **OR (95%CI), *P* value** | | ***n* = 248** | | **OR (95%CI), *P* value** |
| TLR9-1237 T/C *(*rs5743836) | Dominant | | TT | | 148 (74%) | 78 (48.5%) | 1.00 | | 188 (75.8%) | | 1.00 |
| TC + CC | | 52 (26%) | 83 (51.5%) | 3.03 (1.95-4.71), < 0.0001 | | 60 (24.2%) | | 0.91 (0.59-1.40), 0.6600 |
| Recessive | | TT + TC | | 188 (94%) | 122 (75.8%) | 1.00 | | 232 (93.5%) | | 1.00 |
| CC | | 12 (6%) | 39 (24.2%) | 5.01 (2.52-9.94), < 0.0001 | | 16 (6.5%) | | 1.08 (0.50-2.34), 0.8400 |
| Log-additive | |  | |  |  | 2.37 (1.74-3.23), < 0.0001 | |  | | 0.96 (0.70-1.32), 0.8100 |
| Alleles | | T | | 336 (0.84) | 200 (0.62) | 1.00 | | 420 (0.85) | | 1.00 |
| C | | 64 (0.16) | 122 (0.38) | 3.20 (2.25-4.54), < 0.0001 | | 76 (0.15) | | 0.95 (0.66-1.36), 0.7822 |
| GC *vs* CG  OR (95%CI), *P* | Dominant | | | | | 3.46 (2.23-5.37), < 0.0001 | | | | | |
| Recessive | | | | | 4.63 (2.44-8.79), < 0.0001 | | | | | |
| Log-additive | | | | | 2.46 (1.82-3.34), < 0.0001 | | | | | |
| Alleles | | | | | 3.37 (2.41-4.70), < 0.0001 | | | | | |
| TLR9-1486 C/T(rs187084) | Dominant | CC | | 58 (29%) | | 21 (13%) | 1.00 | 46 (18.6%) | | 1.00 | |
| CT + TT | | 142 (71%) | | 140 (87%) | 2.72 (1.57-4.72), < 0.0001 | 202 (81.5%) | | 1.79 (1.15-2.79), 0.0094 | |
| Recessive | CC + CT | | 164 (82%) | | 122 (75.8%) | 1.00 | 182 (73.4%) | | 1.00 | |
| TT | | 36 (18%) | | 39 (24.2%) | 1.46 (0.87-2.43), 0.1500 | 66 (26.6%) | | 1.65 (1.05-2.61), 0.0300 | |
| Log-additive |  | |  | |  | 1.70 (1.23-2.37), 0.0013 |  | | 1.52 (1.15-2.02), 0.0030 | |
| Alleles | C | | 222 (0.56) | | 143 (0.44) | 1.00 | 228 (0.46) | | 1.00 | |
| T | | 178 (0.44) | | 179 (0.56) | 1.56 (1.16-2.09), 0.0035 | 268 (0.54) | | 1.46 (1.12-1.91), 0.0048 | |
| GC *vs* CG  OR (95%CI), *P* | Dominant | | | | | 1.15 (0.72-1.84), 0.5700 | | | | | |
| Recessive | | | | | 0.69 (0.39-1.24), 0.2100 | | | | | |
| Log-additive | | | | | 0.95 (0.69-1.31), 0.7500 | | | | | |
| Alleles | | | | | 0.93 (0.70-1.24), 0.6670 | | | | | |

C: Control; OR: Odds ratio; CI: Confidence interval; GC: Gastric cancer; CG: Chronic gastritis.

**Table 3 Haplotype frequency distribution of TLR9 polymorphisms between GC, CG and control groups**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Haplotypes** | **GC, %** | **C, %** | ***X*2** | ***P* value** | **CG, %** | **C, %** | ***X*2** | ***P* value** | **GC, %** | **CG, %** | ***X*2** | ***P* value** |
| **TLR9-1237/-1486** |
| T-C | 35.2 | 47.7 | 38.284 | ≤ 0.0001 | 40.5 | 48.4 | 5.617 | 0.0178 | 24.9 | 39.7 | 19.098 | ≤ 0.0001 |
| T-T | 36.9 | 36.3 | 0.024 | 0.8772 | 44.2 | 35.6 | 6.778 | 0.0092 | 37.3 | 45.0 | 4.838 | 0.0278 |
| C-T | 18.7 | 8.2 | 17.656 | ≤ 0.0001 | 9.8 | 8.9 | 0.233 | 0.6290 | 18.3 | 9.0 | 15.335 | ≤ 0.0001 |
| C-C | 19.2 | 7.8 | 20.475 | ≤ 0.0001 | 5.5 | 7.1 | 1.000 | 0.3158 | 19.6 | 6.3 | 33.560 | ≤ 0.0001 |

C: Control; GC: Gastric cancer; CG: Chronic gastritis.

**Table 4 Combined effect of TLR9-1237 T/C and TLR9-1486 C/T polymorphisms on risk of GC and CG**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Risk genotype** | | **Groups** | | | **OR (95%CI), *P* value** | | |
| **TLR9*-*1237** | **TLR9*-*1486** | **C,**  ***n* = 200** | **GC,**  ***n* = 161** | **CG,**  ***n* = 248** | **GC × C** | **CG × C** | **GC × CG** |
| TT | CC | 50 | 7 | 38 | 1.00 | 1.00 | 1.00 |
| TC/CC | CC | 5 | 13 | 7 | 18.57 (5.06-68.15), < 0.0001 | 1.842 (0.54-6.25), 0.3665 | 10.08 (2.96-34.24). 0.0002 |
| TT | CT/TT | 98 | 70 | 150 | 5.102 (2.18-11.92), < 0.0001 | 7.737(4.72-12.66), < 0.0001 | 2.533 (1.07-5.95), 0.0307 |
| TC/CC | CT/TT | 47 | 71 | 53 | 10.79 (4.50-25.83), < 0.0001 | 1.484 (0.83-1.64), 0.1911 | 7.272 (3.01-17.56), < 0.0001 |

GC: Gastric cancer; CG: Chronic gastritis.

**Table 5** **Relative gene expression levels of TLR9 for GC and CG**


|  |  |  |
| --- | --- | --- |
| **Variables** | **Cases** | |
| **GC, *n* = 23** | **CG, *n* = 48** |
| Median | 9.24 | 1.55 |
| Range | 3.64-24.06 | 1.04-3.87 |
| *P* value | < 0.00011 | |

1Mann Whitney *U* Test. GC: Gastric cancer; CG: Chronic gastritis.


**Table 6 TLR9 gene expression levels of GC and CG groups to assess influence of polymorphic genotypes**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Groups** | | **TLR9*-*1237T/C *(*rs5743836)** | | | ***P* value** | **TLR9*-*1486 C/T(rs187084)** | | | ***P* value** |
|  | | **TT** | **TC/CC** | |  | **CC** | **CT / TT** | |  |
|  | | **Upregulated cases** | | |  | **Upregulated cases** | | |  |
| GC  (*n* = 26) | Median | 5.24 | | 13.01 | 0.0083 | 7.37 | | 9.90 | 0.8763 |
| Range | 1.72-9.27 | | 7.55-189.00 | 5.74-14.16 | | 2.49-53-75 |
| CG  (*n* = 48) | Median | 1.47 | | 1.45 | 0.8442 | 3.26 | | 1.50 | 0.1515 |
| Range | 0.77-4.19 | | 0.75-3.82 | 1.39-8.46 | | 0.75-3.00 |


GC: Gastric cancer; CG: Chronic gastritis.



**Figure 1** **Relative gene expression levels of TLR9*.*** Comparison between CG and GC groups with the normal mucosa (Median = 1), and between the CG and GC groups (a*P* < 0.0001). Data are presented as the RQ median with interquartile range. Significant difference (*P* < 0.05). GC: Gastric cancer; CG: Chronic gastritis; RQ: Relative quantification.



**Figure 2** **Comparison between *H. pylori*-positive and *H. pylori*-negative groups (a*P* < 0.0001).** Data are presented as the RQ median with interquartile range. Significant difference (*P* < 0.05). RQ: Relative quantification; *H. pylori*: *Helicobacter pylori*.



**Figure 3 Relative expression.** A: Comparison between TLR9-1237TT (wild-type) and TC + CC (polymorphic) in GC (a*P* = 0.0083) and CG (*P* = 0.8763) groups; B: TLR9-1486CC (wild-type) and CT + TT (polymorphic) in GC (*P* = 0.8442) and CG (*P* = 0.1515) groups. Data are presented as the RQ median with interquartile range. Significant difference (*P* < 0.05). CG: Chronic gastritis; GC: Gastric cancer; RQ: Relative quantification.